Drug Profile

Ultra fast-acting insulin lispro biosimilar - Perosphere

Alternative Names: Ultra rapid-acting insulin lispro; URAL

Latest Information Update: 30 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Perosphere
Class Antihyperglycaemics; Insulins; Pancreatic hormones
Mechanism of Action Phosphokinase stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Type 1 diabetes mellitus

Most Recent Events

17 Jan 2019 Perosphere has been acquired by AMAG Pharmaceuticals
25 Jun 2015 Discontinued - Phase-I for Type-1 diabetes mellitus in Germany (SC) before June 2015
30 Jun 2014 Phase-I clinical trials in Type-1 diabetes mellitus in Germany (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com